@misc{Konopka_Kamil_Prognostic_2022,
 author={Konopka, Kamil},
 address={Kraków},
 howpublished={online},
 year={2022},
 school={Rada Dyscypliny Nauki medyczne},
 language={pol; eng},
 abstract={Advanced gastric cancer is an incurable disease with a median overall survival (OS) of 12-13 months. Properly implemented palliative treatment can extend OS to 12-13 months. The purpose of this work is to identify new and verify known prognostic and predictive factors. In the first publication, inflammatory markers were analyzed before chemotherapy. The second study analyzed platelet level (PLT) after initiation of chemotherapy and looked for a relationship between the depth of reduction in PLT and OS. Data from 155 patients with advanced gastric cancer treated in the Department of Oncology at the University Hospital in Cracow between 2012 and 2019 were retrospectively analyzed. In the first publication, initial PVPR (platelets volume to platelets ratio) and NLR (neutrophil to lymphocyte ratio) were shown to be statistically and clinically significant. In the most adjusted model, patients with high levels of PVPR had a 44% lower risk of death (HR = 0.56; 95% CI 0.33- 0.93). In the same model, the risk of death in patients with high NLR values was almost two times higher than in patients with low NLR (HR = 1.95; 95% CI 1.17-3.24). In the second publication, the level of platelet reduction after initiation of chemotherapy showed a strong relationship with OS. This analysis showed that patients in the worst prognostic group (high initial PLT and},
 abstract={low reduction in PLT) have a 3.6 times higher risk of death and a 2.97 times higher risk of death in fully adjusted models.},
 title={Prognostic and predictive factors in advanced gastric cancer},
 type={Praca doktorska},
 keywords={gastric cancer, metastases, chemotherapy, NLR, thrombocytopenia},
}